BRIEF published on 08/27/2024 at 13:05, 7 months 10 days ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 7 months 10 days ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 7 months 10 days ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 9 months 2 days ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 9 months 2 days ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 9 months 2 days ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 9 months 18 days ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 9 months 18 days ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 9 months 18 days ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 10 months 30 days ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 04/07/2025 at 00:05, 7 hours 9 minutes ago Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders
Published on 04/05/2025 at 01:50, 2 days 5 hours ago Battery X Metals Achieves Graphite Recovery Breakthrough in Partnership with Global Top 20 University in Controlled Trials
Published on 04/07/2025 at 07:03, 11 minutes ago Swiss Re to be appointed as co-investment manager of GAM's catastrophe bond and ILS fund range
Published on 04/07/2025 at 07:00, 14 minutes ago Julius Baer further streamlines its organisation to reinforce focus on clients and sustainable growth
Published on 04/06/2025 at 18:20, 12 hours 53 minutes ago EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook
Published on 04/06/2025 at 15:09, 16 hours 5 minutes ago EQS-Adhoc: DEUTZ acquires developer of electrification solutions UMS
Published on 04/04/2025 at 19:00, 2 days 12 hours ago PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 04/07/2025 at 07:01, 13 minutes ago bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 13 minutes ago bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 11 hours ago Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 11 hours ago Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 12 hours ago Reporting on share buyback transactions carried out between March 31 and April 3, 2025
